Stockscreener 앱 받기
35.18
0.85%
-0.30
시장 영업 전:
33.01
-2.17
-6.17%
전일 마감가:
$35.48
열려 있는:
$35.44
하루 거래량:
388.10K
Relative Volume:
0.93
시가총액:
$2.69B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-12.84
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
-5.63%
1개월 성능:
-10.39%
6개월 성능:
-13.86%
1년 성능:
-21.96%
1일 변동 폭
$35.02
$36.22
1주일 범위
$33.81
$38.08
52주 변동 폭
$33.27
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
35.18 | 2.69B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - StockTitan
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Xenon Pharmaceuticals announces executive changes - MSN
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Xenon Pharmaceuticals Advances Clinical Pipeline Amid Financial Losses - TipRanks
Xenon Pharmaceuticals reports Q4 EPS (84c), consensus (84c) - TipRanks
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Xenon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenon Pharmaceuticals Q4 Net Loss Widens -February 27, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88 - Marketscreener.com
Xenon Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:20 pm EST - Marketscreener.com
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Inc. Announces Resignation of Sherry Aulin as Chief Financial Officer, Effective June 30, 2025 - Marketscreener.com
Can Xenon's $754M War Chest Fuel Its Epilepsy Breakthrough? Phase 3 Data Coming 2025 - StockTitan
HC Wainwright Issues Pessimistic Estimate for XENE Earnings - Defense World
What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Ear - GuruFocus.com
What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings - Yahoo Finance
Xenon Pharmaceuticals to Present at TD Cowen Healthcare Conference - TipRanks
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference - The Manila Times
Will Xenon Reveal New Epilepsy Drug Data at Major Healthcare Conference? - StockTitan
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - MarketBeat
TimesSquare Capital Management LLC Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Xenon Pharmaceuticals to Announce Q4 and Full Year 2024 Financial Results - TipRanks
Can Xenon's Promising Epilepsy Drug Pipeline Deliver? Q4 Results Will Tell - StockTitan
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):